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We undertook a prospective active surveillance study 
of invasive group A streptococcal (GAS) disease in Fiji over 
a 23-month period, 2005–2007. We identifi ed 64 cases of 
invasive GAS disease, which represents an average an-
nualized all-ages incidence of 9.9 cases/100,000 popula-
tion per year (95% confi dence interval [CI] 7.6–12.6). Rates 
were highest in those >65 years of age and in those <5 
years, particularly in infants, for whom the incidence was 
44.9/100,000 (95% CI 18.1–92.5). The case-fatality rate 
was 32% and was associated with increasing age and un-
derlying coexisting disease, including diabetes and renal 
disease. Fifty-fi ve of the GAS isolates underwent emm se-
quence typing; the types were highly diverse, with 38 dif-
ferent emm subtypes and no particular dominant type. Our 
data support the view that invasive GAS disease is com-
mon in developing countries and deserves increased public 
health attention.
Invasive disease caused by group A streptococci (GAS) occurs when the bacteria infect a normally sterile site. 
Invasive GAS disease is often life threatening; mortality 
rate is ≈10%–15% in industrialized countries, increasing 
to up to 50% in the presence of streptococcal toxic shock 
syndrome (1,2).
A review of the global effects of invasive GAS dis-
ease in 2005 estimated that at least 663,000 new cases 
and 163,000 deaths occur each year (3). Although >95% 
of these cases and deaths occur in developing countries, 
few data exist about the epidemiology of these infections 
in developing countries. In addition, few data describe the 
clinical signs and symptoms, case-fatality rate, and risk 
factors associated with invasive GAS disease or the molec-
ular epidemiology of invasive GAS disease in developing 
countries because most published reports originate from 
industrialized countries (4–8).
We recently reported incidence of invasive GAS infec-
tion in Fiji from a retrospective study in the years 2000–
2005 (9). This study indicated that potentially substantial 
effects of invasive GAS disease occur in Fiji. We therefore 
designed a prospective study with active surveillance to en-
sure good case ascertainment and the acquisition of more 
detailed clinical information.
Methods
This prospective study was performed at the Colonial 
War Memorial Hospital in Suva, Fiji, during the 23-month 
period from December 5, 2005, through November 5, 2007. 
During the fi rst year of the study, we noticed that a con-
siderable number of invasive group C streptococcal (GCS) 
and group G streptococcal (GGS) infections occurred. We 
therefore amended the protocol midway through the study 
(December 5, 2006) to include cases of invasive GCS and 
GGS infection (year 2). We analyzed 2 datasets: the fi rst 
was the data available for 23 months of invasive GAS in-
fections, and the second was the data available in year 2 for 
the 11 months of surveillance of all invasive β-hemolytic 
streptococcal infections (GAS, GCS, and GGS).
Setting
Fiji is a nation of ≈330 islands located in the West-
ern Pacifi c. It has a population of 827,900 persons consist-
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ing of 2 major racial groups, indigenous Fijians (57.3%) 
and Indo-Fijians (37.6%) (10). Approximately 49% of the 
population lives in rural areas (10). Of 177 nations on the 
United Nations Development Programme Human Devel-
opment Index, Fiji is number 90. Fiji has a gross domestic 
product per capita of US$6,066, and indexes of wealth are 
similar for the 2 major racial groups; Indo-Fijians are at 
a slight disadvantage. The 2002–2003 Household Income 
and Expenditure Survey estimated that 35.6% of the Indo-
Fijian population live in poverty compared with 34.2% of 
the indigenous Fijian population (11,12). Life expectancy 
at birth is 63.8 years for men and 66.8 years for women 
and is similar for both major racial groups (11,12). Fiji has 
an infant mortality rate of 17.2/1,000 population, slightly 
higher for Indo-Fijians at 19.1/1,000 than for indigenous 
Fijians at 16.8/1,000 (11,12). The major hospital, the Co-
lonial War Memorial Hospital (CWMH), is located in the 
capital, Suva, on the main island of Viti Levu, and primar-
ily serves the Central Division, the largest of the 4 admin-
istrative divisions in Fiji. Five subdivisional hospitals are 
located in the Central Division of Fiji, but most seriously 
ill patients are admitted to CWMH. This circumstance is 
due to the 568-bed capacity of CWMH compared with the 
81-bed capacity of all 5 subdivisional hospitals combined. 
CWMH has ≈20,500 admissions per year; the number of 
indigenous Fijians and Indo-Fijians admitted is propor-
tionate to the population of the Central Division. The total 
population of the Central Division in 2007 was 340,843: 
65% indigenous Fijians and 30.2% Indo-Fijians (10). The 
remainder of the population includes a substantial Chinese 
population as well as Europeans and Pacifi c Islanders, in-
cluding persons from Rotuma, a volcanic island >400 km 
north of Fiji (it is politically part of Fiji, but its people are 
ethnically distinct from indigenous Fijians) (13).
Surveillance and Case Defi nitions
Admission registers at CWMH were checked, and 
treating physicians were consulted daily for any admitted 
patient that may have had invasive GAS disease, including 
those admitted with necrotizing fasciitis, sepsis, and soft 
tissue infections. The diagnostic microbiology laboratory at 
CWMH was also contacted daily for any new β-hemolytic 
streptococcal isolates obtained from sterile and nonster-
ile sites. We used a consensus case defi nition of invasive 
GAS disease developed in 2005 by a World Health Orga-
nization/US National Institutes of Health working group; 
the defi nition is currently being prepared for publication 
(F. Rubin, pers. comm.) (Table 1). Cases of streptococcal 
toxic shock syndrome were defi ned according to published 
criteria (14). Clinical data were collected from review of 
the medical records and from information provided by the 
treating physicians when necessary.
Laboratory Methods
All blood cultures collected at CWMH were processed 
in an automated blood culture machine in the diagnostic 
microbiology laboratory. Isolates that were suspected of 
being GAS, GCS, or GGS were subcultured onto sheep 
blood agar and regrown for Lancefi eld grouping (Oxoid; 
Cambridge, UK). Susceptibility testing was performed on 
sheep blood Mueller-Hinton agar by the disk-diffusion 
method by using Clnical Laboratory Standards Institute 
guidelines against a panel of 4 antimicrobial drugs: peni-
cillin (10 μg), erythromycin (15 μg), clindamycin (2 μg), 
and chloramphenicol (30 μg) (Oxoid). Isolates were trans-
ported to the Queensland Institute of Medical Research for 
emm sequence typing according to the standard methods 
developed by the Centers for Disease Control and Preven-
tion (Atlanta, Georgia, USA) (15).
Statistical Calculations
We used the population of the Central Division from 
the 2007 national census as the basis for denominator cal-
culations. Because surveillance occurred during 2005 (1 
month), 2006 (12 months), and 2007 (10 months), we ex-
trapolated a total population fi gure for 2005 and 2006 us-
ing the pro rata difference between the last offi cial census 
in 1996 and the latest census in 2007. In calculating av-
erage annualized rates, the denominator of person-months 
was calculated by multiplying each year’s population by 
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Table 1. Case definitions for invasive GAS disease, Fiji, 2005–2007* 
Disease Case definition
Definite Either of the following: 
1. The isolation of GAS from a normally sterile site (e.g., blood, cerebrospinal fluid, or other sterile fluid/tissue). 
2. Clinical presentation of necrotizing fasciitis with evidence of GAS infection (e.g., the presence of typical gram-
positive cocci on Gram stain or positive streptococcal serology). 
Probable Any of the following: 
1. A classic presentation of necrotizing fasciitis without microbiological confirmation. 
2. Cellulitis in a patient who is moderately or severely unwell (i.e., unwell and history of parenteral antibiotics 
and/or admission to hospital) and microbiological confirmation (i.e., group A streptococcal culture of swab or 
positive streptococcal serology). 
3. Other clinically significant infection in a patient who is moderately or severely unwell (i.e., unwell and history 
of parenteral antibiotics and/or admission to hospital), in conjunction with positive group A streptococcal culture 
from deep wound swab or biopsy from surgical infection site. 
*GAS, group A streptococci. 
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the number of months of surveillance for each year (i.e., 
2005 population by 1 month, 2006 by 12 months, and 2007 
population by 10 months) and adding these totals. The to-
tal number of cases over the 23 months was then divided 
by the total person-months and multiplied by 12 to give 
average annualized incidence rates with binomial exact 
95% confi dence intervals (CI). Incidence rate ratios were 
used to compare rates between ethnic groups. We used χ2 
calculations of odds ratios (ORs) for univariate analysis of 
categorical data. Data were analyzed by using Stata version 
10.0 (StataCorp, College Station, TX, USA).
Ethical Approval
Ethical approval was obtained from the Fiji Nation-
al Research Ethics Review Committee, the Fiji National 
Health Research Committee, the University of Melbourne 
Human Research Ethics Committee, and the Queensland 
Institute of Medical Research Human Research Ethics 
Committee. We asked all patients for their consent for the 
collection of more detailed clinical and outcome data as 
well as for the transport and testing of the clinical isolates. 
Information sheets in Fijian and English were provided to 
potential participants before enrollment. We required that 
all patients provide written informed consent before infor-
mation was collected. Children were only enrolled if a par-
ent or guardian provided written consent, and we also re-
quired written assent from children >10 years of age. When 
patients did not consent, the case was noted for incidence 
calculations, but more detailed clinical and outcome data 
were not collected.
Results
Invasive Group A Streptococcal Infections 
Epidemiologic Data
Sixty-four cases of invasive GAS disease occurred dur-
ing the 23 months of surveillance. Sixty-two cases met the 
criteria for a defi nite case, and 2 cases met the criteria for 
a probable case. The average annualized all-ages incidence 
of invasive GAS disease (both defi nite and probable) in the 
Central Division was 9.9 cases/100,000 population/year 
(95% CI 7.6–2.6). There were an equal number of male and 
female case-patients. The median age of patients with inva-
sive GAS disease was 51.6 years (interquartile range [IQR] 
27.6–66.4 years). The youngest patient was aged 1 month, 
and 7 patients were <1 year of age, representing an incidence 
of 44.9/100,000 population (95% CI 18.1–92.5) in this age 
group (Figure). The peak incidence occurred in patients 
>65 years (incidence 80.6/100,000, 95% CI 46.1–130.8). 
Fifty-three cases occurred in indigenous Fijians (incidence 
13.1/100,000, 95% CI 9.8–17.1), 5 cases in Indo-Fijians (in-
cidence 2.5/100,000, 95% CI 0.8–5.9), and 6 cases in persons 
of other races (incidence 12.8/100,000, 95% CI 4.7–27.8). 
Of the 6 cases in persons of other races, 4 patients were Ro-
tuman (incidence 47.4/100,000, 95% CI 12.9–121.4). When 
adjusted for the population of the Central Division, the in-
cidence rate ratio for invasive GAS disease in indigenous 
Fijians versus other races was 2.9 (95% CI 1.5–6.1).
Clinical Data
Of the 64 case-patients with invasive GAS disease, in-
formed consent to collect clinical and outcome information 
was obtained from 60. Soft tissue infection (with associ-
ated bacteremia) was the most common clinical infection 
(23 cases [38%]; Table 2); followed by bacteremia with no 
clinical focus of infection (17 cases [28%]), and necrotiz-
ing fasciitis (4 cases [7%]). Three cases (5%) fulfi lled the 
criteria for streptococcal toxic shock syndrome; the clini-
cal focus for these infections was soft tissue infection in 
2 case-patients and pneumonia in the third case-patient. 
Group A streptococci were isolated from blood cultures of 
55 (92%) of the 60 case-patients, from both blood culture 
and other sterile fl uid of 4 case-patients, from sterile fl uid 
alone of 3 case-patients, and from nonsterile sites (breast 
abscess fl uid and leg cellulitis swab) of the 2 patients with 
probable cases. GAS was isolated from blood culture for all 
4 case-patients from whom consent to obtain further clini-
cal information was not obtained.
Thirty-eight case-patients (63%) had at least 1 known 
coexisting chronic medical condition (Table 3). Diabetes was 
the most common coexisting condition (25 patients [42%]), 
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Figure. Invasive group A streptococcal disease in the Central 
Division of Fiji, December 5, 2005–November 5, 2007.
Group A Streptococcal Disease, Fiji
and was found in 7 of the 12 patients with soft tissue infec-
tion who were >50 years of age. No signifi cant difference 
was found in the rates of underlying disease for indigenous 
Fijians (62%) compared with rates for persons of other races 
(70%; p = 0.6). Eighteen patients (30%) had current or recent 
impetigo. Impetigo was more common in younger patients 
and was present in 7 of the 10 patients with invasive GAS 
disease who were <5 years of age and in 4 of the 7 patients 
<1 year of age. No cases of varicella-zoster virus infection 
were found in this study, and only 1 patient reported the re-
cent use of a nonsteroidal antiinfl ammatory drug.
Outcome and Case-Fatality Rate Data
Of the 60 case-patients for whom outcome data were 
available, 19 died, representing a case-fatality rate of 32%. 
The case-fatality rate increased with patient age; peak fa-
tality rate was 44% in those >65 years of age. The odds of 
death for patients >50 years compared with those of the rest 
of the patient group was 3.1 (95% CI 0.9–11.7). The young-
est patient to die from invasive GAS disease was 1 year and 
2 months of age; this was the only death in patients <25 
years. No signifi cant difference was found in case-fatality 
rate for indigenous Fijians (32%) compared with that for 
persons of other races (30%; p = 0.9). All deaths occurred 
within 6 days of admission; 5 deaths (26%) occurred with-
in the fi rst 24 hours, 12 deaths (63%) within the fi rst 48 
hours, and 15 deaths (79%) within the fi rst 72 hours. The 
clinical sites of infection in the group of patients that died 
were similar to the pattern seen overall: 7 patients had a 
soft tissue infection, 9 patients had bacteremia alone, 2 pa-
tients had pneumonia, and 1 had necrotizing fasciitis. All 3 
patients with streptococcal toxic shock syndrome died. A 
coexisting chronic medical condition was associated with 
an increased risk for death from invasive GAS disease (OR 
4.6, 95% CI 1.0–27.7). Twelve patients with diabetes died 
(OR 3.7, 95% CI 1–13.7), and 8 patients with renal disease 
died (OR 5.2, 95% CI 1.2–24.2).
Fourteen patients (23%) required surgery as part of 
their treatment regimen, and 2 of these patients had a leg 
amputated below the knee. Five patients (8%) were admit-
ted to the intensive care unit, and 1 patient required me-
chanical ventilation. Twenty-nine patients (48%) were ad-
mitted to the hospital for >10 days. Of the 41 survivors of 
invasive GAS infection, 16 had a residual disability (39%). 
Overall, 35 patients (58%) died or had a disability as a re-
sult of an invasive GAS infection.
Laboratory Data
Susceptibility testing was performed on 57 of the 60 
isolates, and all 57 isolates were susceptible to all 4 anti-
microbial drugs tested. Fifty-fi ve of the 60 isolates were 
able to be emm sequence typed (Table 4); 37 different emm 
types and 38 different emm subtypes with no particular 
dominant types emerged from this series. The most com-
mon subtypes were emm100 and emm76.4 (4 cases each), 
followed by emm11, emm33, and emm106 (3 cases each). 
No emm type 1 isolates were found. Eight of the 55 isolates 
emm typed were in nonindigenous Fijian patients, and of 
these, only 1 emm subtype was also observed among indig-
enous Fijian patients.
Invasive β-hemolytic Streptococcal Infections 
after December 5, 2006
Epidemiologic Data
In addition to the GAS infections, 4 cases of invasive 
GCS infection and 14 cases of invasive GGS infection 
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Table 2. Clinical signs and symptoms in patients with invasive GAS infection, by age, Fiji, 2005–2007* 
No. patients by age group 
Clinical signs/symptoms 0–14 y 15–49 y >50 y Total no. (%) patients 
Soft tissue infection 2 9 12 23 (38) 
Bacteremia with no clinical focus 5 5 7 17 (28) 
Septic arthritis 2 1 5 8 (13) 
Necrotizing fasciitis – 2 2 4 (7) 
Pneumonia 2 – 2 4 (6)
Gynecologic infection – 1 1 2 (3) 
Osteomyelitis 1 – – 1 (2)
Peritonitis – – 1 1 (2)
Total no. (%) patients 12 (20) 18 (30) 30 (50) 60
*GAS, group A streptococci. 
Table 3. Underlying coexisting medical conditions in patients with 
invasive GAS disease, Fiji, 2005–2007* 
Condition No. (%) patients  
Diabetes 25 (42)
Renal disease 13 (22) 
Cardiac disease 13 (22) 
Malignancy 5 (8)
Immunosuppression 2 (3)
Lung disease 3 (5) 
Liver disease 1 (2) 
Any coexisting condition 38 (63) 
Only 1 coexisting condition 21 (35) 
2 coexisting conditions† 11 (18) 
>2 coexisting condition† 6 (10) 
*GAS, group A streptococci. 
†Nine patients had diabetes and renal disease. 
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were found in year 2, making a total of 44 cases of invasive 
β-hemolytic streptococcal infection during the 11 months 
of surveillance in year 2. This represents an annualized all-
ages incidence of 14.1 cases/100,000 population/year (95% 
CI 10.2–18.9), an incidence rate of invasive GCS disease 
of 1.3/100,000 (95% CI 0.3–3.3), and an incidence rate of 
invasive GGS disease of 4.5/100,000 (95% CI 2.5–7.5). 
Overall, 24 male patients and 20 female patients were in-
fected. The peak incidence was in those >65 years of age 
(incidence 104.7/100,000, 95% CI 50.2–192.4), and 3 cas-
es occurred in infants. Thirty-four cases occurred in indig-
enous Fijians (incidence 17.4/100,000, 95% CI 12–24.3), 
and 10 cases occurred in persons of other races (incidence 
8.6/100,000, 95% CI 4.1–15.8); incidence rate ratio for in-
digenous Fijians was 2 (95% CI 1–4.6).
Clinical, Outcome, and Laboratory Data 
Relating to GCS and GGS Disease
Of the 18 cases of invasive GCS and GGS disease, in-
formed consent to collect clinical and outcome information 
was obtained for 12 of 14 case-patients with invasive GGS 
infection and for all 4 case-patients with invasive GCS in-
fection. The clinical spectrum of GCS and GGS infection 
was similar to that for invasive GAS infection, although the 
number of patients with bacteremia with no clinical focus 
was higher, and a case of meningitis in a neonate caused 
by GCS was added (Table 5). Similar to the experience of 
patients with invasive GAS disease, a high proportion of 
patients with invasive GCS and GGS disease had a coexist-
ing chronic medical condition (69%); 44% of patients had 
cardiac disease, 31% of patients had diabetes, and 6% had 
renal disease. Six deaths occurred (38%). emm sequence 
typing was performed on 12 isolates (2 GCS and 10 GGS), 
and 9 different emm types were found (Table 4). One was 
emm12, which is normally associated with GAS.
Discussion
This study confi rms the extensive effects that inva-
sive GAS infections have in Fiji and adds to the small 
amount of existing data indicating that the incidence and 
case-fatality rates of these infections are ≈3–4 times high-
er in developing countries than in industrialized coun-
tries. A study in Kenya found that the incidence of GAS 
bacteremia in children <15 years of age was 13/100 000 
population and that mortality rate was 25% (16), simi-
lar to the results in our study. In indigenous populations 
in wealthy countries, such as Aboriginal Australians and 
Native Americans, the all-ages incidence of invasive GAS 
disease is as high as 82.5/100,000 and 46/100,000, respec-
tively (2,17,18).
We observed a nearly 3-fold higher risk for invasive 
GAS disease in indigenous Fijians. The reasons are not 
entirely clear and do not appear to be related to socioeco-
nomic status or to coexisting conditions, including diabe-
tes; detailed studies of diabetes in Fiji have shown that the 
prevalence of diabetes is higher in Indo-Fijians (19,20) 
than in indigenous Fijians. One possible explanation is that 
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Table 4. emm sequence subtypes of 55 invasive GAS isolates 
and 12 invasive GCS and GGS isolates from hospital 
surveillance, Fiji, 2005–2007*  
GAS emm subtype No. isolates (n = 55) 
 emm11† 3
 emm14.4† 1
 emm15.1 1
 emm18.12† 1
 emm19.4† 1
 emm22† 1
 emm33† 3
 emm52.1 1
 emm53 1
 emm57 2
 emm58 1
 emm60.1 1
 emm60.2 1
 emm63.3 1
 emm69.1 1
 emm70 1
 emm73 2
 emm75.1† 1
 emm76.4† 4
 emm77† 2
 emm81.3 1
 emm82.1 1
 emm86.2 1
 emm87 1
 emm100 4
 emm101† 1
 emm104 1
 emm105 1
 emm106 3
 emm110 2
 emm113 1
 emm116.1 1
 emm123 1
 st2037 1
 st2147 1
 st6030.1 1
 st854.1 2
 stD631 1
GCS and GGS emm subtype No. isolates (n = 12) 
 emm12.8† 1
 stC36 2
 stC922 1
 stG245 2
 stG643 1
 stG652 1
 stG840 1
 stG5420 1
 stc74a 2
*GAS, group A streptococci; GCS, group C streptococci; GGS, group G 
streptococci. 
†emm subtypes included in the 26-valent vaccine. 
Group A Streptococcal Disease, Fiji
GAS skin disease is more extensive in indigenous Fijian 
communities and that this leads to a higher risk for invasive 
GAS disease. We have observed a higher prevalence in 
Fiji of bacterial skin disease in indigenous Fijian children 
(A. Steer, unpub. data), and high rates of GAS skin disease 
have been found in Pacifi c Islanders in other parts of the 
world, including in Maoris and other Polynesians in New 
Zealand (21,22).
In most industrialized countries, the annual incidence 
of invasive GAS disease is 2.5–3.5/100,000 population 
(8,23), and the case-fatality rate is 7%–15% (6,8,23–26). 
Although some epidemiologic similarities were found be-
tween invasive GAS disease in these countries and in Fiji, 
such as the high rates for elderly persons with coexisting 
medical conditions, as well as in the clinical spectrum of 
disease, major differences stand out. Not only was the all-
ages incidence rate higher, but we also found that the inci-
dence rate for children in Fiji was disproportionately high 
when compared with rates in industrialized countries. For 
example, the average annualized incidence rate for infants 
in the United States in 2000–2004 was 5.3/100,000, where-
as in Fiji it was 44.9/100,000 (8).
The high case-fatality rate in our study (32%) may re-
fl ect the late appearance of clinical signs and symptoms, 
particularly because such a high proportion of deaths oc-
curred in the fi rst 24–48 hours after admission. It may also 
refl ect inadequate treatment of invasive GAS infection, 
particularly of early sepsis, possibly because of reduced ac-
cess to intensive care facilities and advanced therapies. The 
rate of diabetes was also higher in our study than in other 
studies, potentially further increasing the case-fatality rate.
The emm typing profi le of invasive GAS isolates was 
different than that in industrialized countries. In most epi-
demiologic studies in wealthy countries, a high proportion 
of disease is caused by a small number of emm types that 
include emm1 (22% of emm types in the United States), 
emm3 (9%), and emm28 (9%) (8). None of these emm types 
were found in our study, and we observed a lack of domi-
nant emm types. The diversity in emm types may refl ect the 
high diversity of GAS in impetigo lesions, as can be seen in 
tropical settings other than Fiji (27).
We observed a substantial number of non-GAS inva-
sive cases in the second year of the study after we expanded 
our surveillance to include these cases. Individual cases of 
GCS and GGS invasive disease have been described be-
fore (28,29), but prospective surveillance has not been per-
formed. Our data suggest that surveillance of invasive GAS 
disease in developing countries should also include surveil-
lance of invasive GCS and GGS disease because the disease 
profi le of these organisms is similar and because control 
strategies, including vaccines that can offer cross-protection 
between Lancefi eld groups, may also be similar.
Identifi cation of factors associated with invasive GAS 
disease, in particular deaths from invasive GAS disease, 
can guide disease prevention and disease management ef-
forts. In adults, diabetes was an important risk factor that 
was associated with death. In children, impetigo appeared 
to be associated with invasive GAS disease. Control of dia-
betes in the elderly and control of impetigo in the young 
may be important disease prevention public health goals. 
With so many deaths occurring shortly after hospital ad-
mission, improved recognition and case management of 
early sepsis may be important disease management goals. 
The fi ndings of this study also have implications for GAS 
vaccine development. Several GAS antigens have been 
identifi ed as potential vaccine candidates. However, only 1 
GAS vaccine, a 26-valent M protein vaccine, has reached 
phase I and II clinical trials (30). Serotypes included in this 
vaccine were chosen if they were common emm types in 
the United States (31,32). Although clinical development 
of the 26-valent vaccine is in its early stages, our results 
raise concerns about the applicability of this vaccine to de-
veloping country settings, because only 10 of 37 emm types 
in our study are types included in the vaccine, accounting 
for 33% of GAS isolates.
Our study confi rms that invasive disease caused by 
GAS and other β-hemolytic streptococci has substantial ef-
fects in Fiji. This study provides the detailed epidemiologic 
and clinical data on invasive GAS infections from a devel-
oping country.
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Table 5. Clinical signs and symptoms of invasive GCS and GGS 
infection, Fiji, 2005–2007* 
Clinical signs/symptoms 
GCS 
infection
GGS 
infection Total 
Bacteremia without clinical 
focus
– 7 7
Soft tissue infection 1 3 4
Endocarditis 1 1 2
Arthritis – 1 1
Pneumonia 1 – 1
Meningitis 1 – 1
Total 4 12 16
*GCS, group C streptococci; GGS, group G streptococci. 
RESEARCH
dren’s Hospital in Melbourne. His work in the Fiji Islands is fo-
cused on investigating the epidemiology of group A streptococcal 
infections as part of a project aimed at development of a novel 
group A streptococcal vaccine.
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